SCHEMBL13049693

SCHEMBL13049693

Nc1cccc(-c2oc3ccccc3c2CO)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.48
▸ KDM4E B2RXH2 7/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ MEN1 O00255 8/20 0.43
▸ KMT2A Q03164 8/20 0.43
▸ HPGD P15428 4/20 0.43
▸ CYP3A4 P08684 4/20 0.43
▸ CYP2D6 P10635 3/20 0.43
▸ CYP2C9 P11712 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ATM Q13315 2/20 0.41
▸ RCE1 Q9Y256 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ DDR2 Q16832 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ MECP2 P51608 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049691 0.84 MEN1 (0.43) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL2962849 0.82 KMT2A (0.53) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049690 0.82 MEN1 (0.60) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049687 0.79 KMO (0.47) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049762 0.79 MEN1 (0.43) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049766 0.77 MAPT (0.49) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049706 0.75 PTPN1 (0.45) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL13049702 0.74 MEN1 (0.47) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049689 0.74 MEN1 (0.47) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL13049701 0.74 LMNA (0.57) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 MAPT 170/4885KDM4E 4759/4885ALDH1A1 2902/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 MAPT 169/4885KDM4E 4807/4885ALDH1A1 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback